Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Venetoclax New Formulation in Healthy Females
NCT06070948Phase 1Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- Oct 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of venetoclax in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Maximum Observed Plasma Concentration, Time to Cmax and 5 more. Planned start Oct 2023; status: withdrawn.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06070948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06070948.